Table showing Safety - prescribing safety indicators

|  |
| --- |
| ***Purpose*:**  |
| To identify patients at high risk of adverse drug reactions and medicines-related harm in primary care. |
| ***Units of measure:***  |
| **Prescribing Safety Indicators related to acute kidney injury (AKI)*** Number of patients on the CKD register (CKD stage 3–5) who have received a repeat prescription for an NSAID within the last 3 months.
* Number of patients who are not on the CKD register but have an eGFR of < 59 ml/min and have received a repeat prescription for an NSAID within the last 3 months.
* Number of patients with concurrent prescriptions of an NSAID, renin‑angiotensin system (RAS) drug and a diuretic.
* Number of patients aged 75 and over with a current prescription for an ACE Inhibitor or loop diuretic without a check of renal function and electrolytes in the previous 15 months.

**Prescribing Safety Indicators related to bleeds*** Number of patients with a peptic ulcer who have been prescribed NSAIDs without a PPI.
* Number of patients with concurrent prescriptions of warfarin and an oral NSAID.
* Number of patients with concurrent prescriptions for a DOAC and an oral NSAID.
* Number of patients aged 65 years or over prescribed an NSAID plus aspirin and/or clopidogrel but without gastroprotection (PPI or H2-receptor antagonist).
* Number of patients with concurrent prescriptions of an oral anticoagulant (warfarin or DOAC) and an SSRI.

**Prescribing Safety Indicators related to cognition*** Number of patients aged 65 years or over prescribed an antipsychotic.
* Number of patients aged 75 and over with an Anticholinergic Effect on Cognition (AEC) score of 3 or more for items on active repeat.

**Prescribing Safety Indicators specific to females*** Number of female patients with a current prescription of oestrogen-only hormone replacement therapy (HRT) without any hysterectomy READ/SNOMED codes.
* Number of female patients with a past medical history of venous or arterial thrombosis who have been prescribed combined hormonal contraceptives.
* Number of female patients aged 14–55 with a prescription for sodium valproate.
* Number of female patients aged 14-55 with a prescription for oral retinoids.

**Prescribing Safety Indicators related to ‘other’*** Number of patients under 16 with a current prescription of aspirin.
* Number of patients with asthma who have been prescribed a beta-blocker.
* Number of patients with concurrent prescriptions of verapamil and a beta‑blocker.
 |
| ***Target for 2021–2022:*** |
| No target set |